The effect of peripheral blood lymphocyte stimulation on zeta chain expression and IL-2 production in Hodgkin's disease

British Journal of Cancer

Volumn 84, Issue 10, 2001, Pages 1339-1343

  Frydecka, I ^a,b   Bocko, D ^b   Kosmaczewska, A ^b   Ciszak, L ^b   Morilla, R ^c  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Hodgkin's disease; Lymphocytes; Stimulation; Zeta chain

Indexed keywords

CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 2; MONOCLONAL ANTIBODY CD3; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ZETA CHAIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER REGRESSION; CLINICAL ARTICLE; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HODGKIN DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; LYMPHOCYTE ACTIVATION; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; ANTIGENS, CD56; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DISEASE-FREE SURVIVAL; FEMALE; HODGKIN DISEASE; HUMANS; INTERLEUKIN-2; KILLER CELLS, NATURAL; MALE; MEMBRANE PROTEINS; MIDDLE AGED; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT PROTEINS; REFERENCE VALUES; T-LYMPHOCYTES;

EID: 0035906833     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2001.1792     Document Type: Article

References (20)

1. Monoclonal antibodies reactive with T-cell receptor zeta chain: Production and characterisation using a new method
2. Fc-gamma receptor type III (CD 16) is included in zeta NK receptor complex expressed by human natural killer cells
3. Report of the committee of Hodgkin's disease staging classification
4. The decreased expression of CD3 zeta chain in cancer patients is not reversed by IL-2 administration
5. Loss of T-cell receptor zeta and p56lck in T-cell infiltrating human renal cell carcinoma
6. Alterations in signal-transducing molecule CD3 zeta in patients with neoplastic diseases
7. Expression of signal-transducing zeta chain in peripheral blood lymphocytes and natural killer cells in patients with Hodgkin's disease in different phases of the disease
8. Transfer of the interleukin-2 gene into human cancer cells induces specific antitumour recognition and restores the expression of CD3/T receptor associated signal transduction molecules
9. The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathway
10. Tumour induced immune dysfunction
11. Alterations in the signal-transducing molecules oft cells and NK cells in colorectal tumour-infiltrating, gut mucosal and peripheral lymphocytes: Correlation with the stage of the disease
12. Signalling events in T lymphocytes leading to cellular activation or programmed cell death
13. Decreased expression of the signal-transducing zeta chains in tumour infiltrating T-cells and NK cells of patients with colorectal carcinoma
14. Expression and activity of signalling molecules in T lymphocytes obtained from patients with metastatic melanoma before, and after interleukin-2 therapy
15. Variable expression of CD3 zeta chain in tumour-infiltrating lymphocytes (TIL) derived from renal-cell carcinoma: Relationship with TIL phenotype and function
16. Tyrosine phosphorylation of the FcRIII CD16: Zeta complex in human natural killer cells. Induction by antibody-dependent cytotoxicity but not by natural killing
17. Molecular cloning of the zeta chain of the T cell antigen receptor
18. Signaling defects in T lymphocytes of patients with malignancy
19. Interleukin-2 restores CD3 zeta chain expression but fails to generate tumour-specific lyric activity in tumour-infiltrating lymphocytes derived from human colorectal hepatic metastases
20. Alterations in T cell receptor and signal transduction molecules in melanoma patients